Loading institutional data...
Loading institutional data...
Held by 641 of 5,944 reporting institutions (98th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Modest payoff on reinvested capital. Current ROIC on all capital: 3%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $111M covers the $0 due within a year 110600000.0× over. Scheduled principal only (excludes interest & revolver draws). As of 2021-10-31 (10-K).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest is easily covered by operating profit. Effective rate ~4.0% on $2.5B of debt.
Cash of $111M fully covers short-term debt of $48M.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.09B 100.0% | $3.90B 100.0% | $3.59B 100.0% | $3.31B 100.0% | $2.92B 100.0% | $2.43B 100.0% | $2.65B 100.0% | $2.53B 100.0% | $2.14B 100.0% | $1.97B 100.0% |
| Cost of Revenue | $1.41B 34.5% | $1.30B 33.4% | $1.24B 34.4% | $1.17B 35.3% | $966.7M 33.1% | $896.1M 36.9% | $896.6M 33.8% | $900.5M 35.6% | $773.2M 36.1% | $793.7M 40.4% |
| Gross Profit | $2.68B 65.5% | $2.60B 66.6% | $2.36B 65.6% | $2.14B 64.7% | $1.96B 66.9% | $1.53B 63.1% | $1.76B 66.2% | $1.63B 64.4% | $1.37B 63.9% | $1.17B 59.6% |
| Research & Development | $172.2M 4.2% | $155.1M 4.0% | $137.4M 3.8% | $110.3M 3.3% | $92.7M 3.2% | $93.3M 3.8% | $86.7M 3.3% | $84.8M 3.3% | $69.2M 3.2% | $65.4M 3.3% |
| Selling, General & Admin | $1.63B 39.8% | $1.53B 39.4% | $1.50B 41.8% | $1.34B 40.6% | $1.21B 41.4% | $992.5M 40.8% | $996.2M 37.5% | $973.3M 38.4% | $799.1M 37.4% | $722.8M 36.8% |
| Operating Income | $682.9M 16.7% | $705.7M 18.1% | $533.1M 14.8% | $507.6M 15.3% | $505.8M 17.3% | $311.8M 12.8% | $546.7M 20.6% | $403.1M 15.9% | $429.1M 20.1% | $324.1M 16.5% |
| Interest Expense | $100.0M 2.4% | $114.3M 2.9% | $105.3M 2.9% | $57.3M 1.7% | $23.1M 0.8% | $36.8M 1.5% | $68.0M 2.6% | $82.7M 3.3% | $33.4M 1.6% | $26.2M 1.3% |
| Other Income (Expense), net | -$16.4M -0.4% | -$9.1M -0.2% | -$14.9M -0.4% | $25.0M 0.8% | $8.8M 0.3% | -$8.5M -0.3% | -$1.3M -0.0% | $11.5M 0.5% | -$1.7M -0.1% | -$2.3M -0.1% |
| Pretax Income | $566.5M 13.8% | $582.3M 14.9% | $412.9M 11.5% | $475.3M 14.4% | $491.5M 16.8% | $266.5M 11.0% | $477.4M 18.0% | $331.9M 13.1% | $394.0M 18.4% | $295.6M 15.0% |
| Income Tax Expense | $191.6M 4.7% | $190.0M 4.9% | $118.7M 3.3% | $89.5M 2.7% | -$2.45B -83.9% | $28.1M 1.2% | $10.7M 0.4% | $192.0M 7.6% | $21.1M 1.0% | $20.7M 1.1% |
| Net Income | $374.9M 9.2% | $392.3M 10.1% | $294.2M 8.2% | $385.8M 11.7% | $2.94B 100.8% | $238.4M 9.8% | $466.7M 17.6% | $139.9M 5.5% | $372.9M 17.4% | $273.9M 13.9% |
| Per Share | ||||||||||
| EPS (Basic) | $1.88 | $1.97 | $1.49 | $1.95 | $59.80 | $4.85 | $9.44 | $2.85 | $7.63 | $5.65 |
| EPS (Diluted) | $1.87 | $1.96 | $1.48 | $1.94 | $59.16 | $4.81 | $9.33 | $2.81 | $7.52 | $5.59 |
| Weighted Avg Shares (Basic) | 199.1M | 198.9M | 197.9M | 197.4M | 49.2M | 49.1M | 49.4M | 49.1M | 48.9M | 48.5M |
| Weighted Avg Shares (Diluted) | 200.0M | 200.4M | 199.3M | 198.8M | 49.8M | 49.6M | 50.0M | 49.7M | 49.6M | 49.0M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $53.78 today, the market must believe free cash flow compounds 17.6%/yr for a decade (off $312M normalized FCF).
The market's 17.6% is more optimistic than its 9-yr track record.
2-stage DCF · 0.20B shares · net debt $2.4B
mean 19.9% · volatility σ 76% · implied rate exceeded in 4/9 yrs
Central path = implied 17.6%/yr growth; shaded band = ±1σ (76%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Earnings are backed by cash (FCF ≥ net income) — high quality. Lower/negative accruals = higher quality (Sloan).
Comfortably covers interest; leverage falling year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $290M buybacks = $290M returned on $434M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
EOD close · as of 2026-09-17
No material risks flagged.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 35.6 | 33.8 | 36.9 | 33.1 | 35.3 | 34.4 | 33.4 | 34.5 |
| Gross Profit | 64.4 | 66.2 | 63.1 | 66.9 | 64.7 | 65.6 | 66.6 | 65.5 |
| R&D | 3.3 | 3.3 | 3.8 | 3.2 | 3.3 | 3.8 | 4.0 | 4.2 |
| SG&A | 38.4 | 37.5 | 40.8 | 41.4 | 40.6 | 41.8 | 39.4 | 39.8 |
| Operating Income | 15.9 | 20.6 | 12.8 | 17.3 | 15.3 | 14.8 | 18.1 | 16.7 |
| Income Tax | 7.6 | 0.4 | 1.2 | -83.9 | 2.7 | 3.3 | 4.9 | 4.7 |
| Net Income | 5.5 | 17.6 | 9.8 | 100.8 | 11.7 | 8.2 | 10.1 | 9.2 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on COO: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| COO | $10.5B | 28.8× | 12.2× | 2.6× | 5.1% | 65.5% | 9.2% | 4.6% | 3.5% | 2.4× | 641 |
Peers = companies sharing COO's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.